SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is seeing intense community engagement and active institutional accumulation ahead of highly anticipated 52-week clinical trial data and upcoming investor conferences. Investors are closely tracking these catalysts as potential triggers for a long-awaited stock rerating, with significant discussion focused on the firm's competitive positioning within the inflammatory disease market.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust ETF is trending as investors weigh Bitcoin's recent price volatility against ongoing institutional adoption and broader geopolitical uncertainties. Community discussions are heavily focused on navigating potential market pullbacks, debating the validity of treasury holdings in related crypto stocks, and speculating on how macroeconomic shifts like interest rate forecasts might impact future asset rotations.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as investors focus on its critical role in advanced semiconductor packaging and the anticipated growth of domestic chip infrastructure. The community is actively discussing the stock's long-term potential as a bottleneck-relieving partner for major semiconductor giants, while watching for technical strength amidst broader market volatility.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The iShares Russell 2000 ETF (IWM) is currently in focus as investors analyze a massive rotation out of large-cap technology into small-cap value and cyclicals. The community is actively debating the sustainability of this price action amid shifting macroeconomic expectations, persistent inflationary pressures, and the potential impact of Federal Reserve policy decisions on small-cap liquidity.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is trending as investors aggressively position for the AI infrastructure buildout, focusing on the critical bottleneck of data center power delivery and thermal management. The community is actively discussing the company's dominant role in liquid cooling solutions as hyperscale demand intensifies, fueling a bullish sentiment around its significant order backlog and capacity expansion.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market volatility as investors weigh the company's long-term potential in data-driven oncology against concerns over capital efficiency and insider selling. The stock remains a focal point for community debate, with bulls highlighting its expanding AI platform and high-profile partnerships, while bears emphasize high short interest and questions surrounding long-term profitability.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently a battleground for investors as it trades near multi-year lows, sparking intense debate between those viewing it as a deep-value accumulation opportunity due to its real-world institutional adoption and those concerned about its prolonged market underperformance. While the community remains polarized over the technical resilience of the network, many are actively tracking potential regulatory catalysts and institutional inflow to determine if the asset is entering a base-building phase or remains a long-term value trap.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLA Corp is trending as investors reassess its essential role in the semiconductor ecosystem, weighing its near-monopoly in process control and yield management against broader volatility in wafer fab equipment spending. The community is actively debating the company's valuation in the context of long-term AI infrastructure build-out and how it compares to equipment peers amidst fluctuating demand for advanced manufacturing nodes.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is drawing significant investor interest as the market closely monitors upcoming Phase 3 clinical data for its mental health treatment programs. The community is actively debating the stock's potential for a breakthrough while weighing the company's cash runway and the broader risks inherent in the biotech sector.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

The Vanguard S&P 500 ETF is trending as investors weigh strong corporate earnings and AI-driven growth against ongoing geopolitical uncertainty and recent hawkish signals from the Federal Reserve. Community discussion remains heavily polarized between proponents of long-term passive index investing and those concerned about market breadth and potential volatility linked to global conflicts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -20.00% and +15.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

HC Wainwright Expects Weaker Earnings for LENZ Therapeutics

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Analysts at HC Wainwright reduced their Q1 2026 earnings estimates for LENZ Therapeutics in a research note issued to investors on Tuesday, April...

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm...

LENZ Therapeutics (NASDAQ:LENZ) Price Target Cut to $48.00 by Analysts at HC Wainwright

HC Wainwright reduced their target price on LENZ Therapeutics from $56.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday...

Aberdeen Group plc Increases Holdings in LENZ Therapeutics, Inc. $LENZ

Aberdeen Group plc lifted its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 274.4% during the fourth quarter, according to the company in its most recent filing with...

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat.com reports. One...

HC Wainwright Issues Positive Forecast for LENZ Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for LENZ Therapeutics in a report issued on...

Citigroup Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price

Citigroup decreased their price objective on shares of LENZ Therapeutics from $52.00 to $26.00 and set a "buy" rating for the company in a report on Thursday...

FY2028 EPS Forecast for LENZ Therapeutics Lowered by Analyst

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for LENZ Therapeutics in a research note issued on Wednesday, March 25th. HC Wainwright analyst M. Caufield now anticipates that the company will earn $0.62 per share for the y...

Bank of America Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price

Bank of America decreased their target price on shares of LENZ Therapeutics from $35.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday...

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

LENZ Therapeutics Inc.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$1.07	--	--	N/A
Q1 '26	-$1.05	-$1.32	-25.99%	MISSED
Q4 '25	-$0.91	-$1.16	-27.71%	MISSED
Q3 '25	-$0.69	-$0.59	14.78%	BEAT
Q2 '25	-$0.61	-$0.53	13.15%	BEAT

LENZLENZ Therapeutics Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest LENZ News